RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder
Trial details
- Registry ID
- NCT01490086
- Phase
- Phase 2
The FDA approved aripiprazole (Abilify) on 15 Nov 2002.
Drug identity checked against registry records
Also recorded as Abilify
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| RP5063 in Subjects With Schizophrenia or Schizoaffective DisorderNCT01490086 | Reviva Pharmaceuticals | Phase 2 | Completed | 2013-03Actual |
| Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic MedicationsNCT07565428 | Minerva Neurosciences | Phase 3 | Recruiting | 2027-12Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2002-11-15Day | aripiprazole | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA021436", "applicant_as_listed_by_fda": "OTSUKA", "brand_names": ["ABILIFY"], "active_ingredients": ["ARIPIPRAZOLE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20021115", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |